Telix Pharmaceuticals Limited (TLPPF)
USD 18.0
(13.21%)
USD 18.0
(13.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 402.22 Million AUD | 57.52% |
| 2022 | 255.35 Million AUD | 132.53% |
| 2021 | 109.81 Million AUD | -30.42% |
| 2020 | 157.82 Million AUD | 53.81% |
| 2019 | 102.6 Million AUD | 33.76% |
| 2018 | 76.7 Million AUD | 50.13% |
| 2017 | 51.09 Million AUD | 0.0% |
| 2000 | 9.39 Million AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 429.99 Million AUD | -29.6% |
| 2024 Q2 | 745.95 Million AUD | 166.04% |
| 2023 Q4 | 402.22 Million AUD | 0.98% |
| 2023 Q1 | 310.33 Million AUD | 21.53% |
| 2023 Q2 | 310.33 Million AUD | 0.0% |
| 2023 Q3 | 398.3 Million AUD | 28.35% |
| 2023 FY | 402.22 Million AUD | 57.52% |
| 2022 Q4 | 255.35 Million AUD | 0.0% |
| 2022 Q2 | 215.94 Million AUD | 0.0% |
| 2022 Q3 | 255.35 Million AUD | 18.25% |
| 2022 Q1 | 215.94 Million AUD | 96.65% |
| 2022 FY | 255.35 Million AUD | 132.53% |
| 2021 Q3 | 109.81 Million AUD | -14.77% |
| 2021 Q4 | 109.81 Million AUD | 0.0% |
| 2021 Q2 | 128.84 Million AUD | 0.0% |
| 2021 Q1 | 128.84 Million AUD | -18.36% |
| 2021 FY | 109.81 Million AUD | -30.42% |
| 2020 Q3 | 157.82 Million AUD | 59.39% |
| 2020 Q1 | 93.86 Million AUD | -8.52% |
| 2020 Q4 | 157.82 Million AUD | 0.0% |
| 2020 FY | 157.82 Million AUD | 53.81% |
| 2020 Q2 | 99.01 Million AUD | 5.49% |
| 2019 FY | 102.6 Million AUD | 33.76% |
| 2019 Q1 | 65.49 Million AUD | -14.62% |
| 2019 Q2 | 65.49 Million AUD | 0.0% |
| 2019 Q4 | 102.6 Million AUD | 0.0% |
| 2019 Q3 | 102.6 Million AUD | 56.66% |
| 2018 Q1 | 48.51 Million AUD | -5.06% |
| 2018 FY | 76.7 Million AUD | 50.13% |
| 2018 Q4 | 76.7 Million AUD | -0.0% |
| 2018 Q3 | 76.7 Million AUD | 58.13% |
| 2018 Q2 | 48.51 Million AUD | 0.0% |
| 2017 FY | 51.09 Million AUD | 0.0% |
| 2017 Q2 | 6.92 Million AUD | 0.0% |
| 2017 Q3 | 51.09 Million AUD | 637.71% |
| 2017 Q4 | 51.09 Million AUD | 0.0% |
| 2017 Q1 | 6.92 Million AUD | 0.0% |
| 2000 FY | 9.39 Million AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | -3711.086% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2662.459% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -208.901% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1339.386% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -113645.097% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -58406.21% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -20440.51% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -17412107.792% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -52092.971% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -72750.467% |
| Qrons Inc. | 420.00 USD | -95767042.857% |
| Skye Bioscience, Inc. | 11.94 Million USD | -3268.578% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -83599.124% |
| Rebus Holdings, Inc. | 5000.00 USD | -8044340.0% |
| CSL Limited | 38.02 Billion USD | 98.942% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -663.215% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -935.4% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -5471.125% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -526685.761% |
| SQZ Biotechnologies Company | 107.18 Million USD | -275.253% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -27987.501% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -555723.948% |
| Mesoblast Limited | 667.9 Million USD | 39.778% |
| Marizyme, Inc. | 22.01 Million USD | -1727.03% |
| Genus plc | 1.02 Billion USD | 60.908% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -29511.007% |
| Pharming Group N.V. | 462.85 Million USD | 13.1% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -12040.674% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -80499.312% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -64050.239% |
| ContraFect Corporation | 20.67 Million USD | -1845.075% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -102937.15% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -105144.952% |
| IMV Inc. | 31.33 Million USD | -1183.669% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -9601.396% |
| MultiCell Technologies, Inc. | 126.22 USD | -318667306.116% |
| ONE Bio Corp. | 70.08 Million USD | -473.902% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -42703.736% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -212.989% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -93068.626% |
| Q BioMed Inc. | 3.51 Million USD | -11341.333% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1043.358% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -153844.664% |
| Biomind Labs Inc. | 73.81 Thousand USD | -544775.98% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 9.878% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -27661.6% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1240.072% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -14545.773% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -15351.084% |
| GB Sciences, Inc. | 103.44 Thousand USD | -388738.19% |
| Alpha Cognition Inc. | 2.45 Million USD | -16302.696% |
| HST Global, Inc. | 1526.00 USD | -26357829.227% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -40612.089% |
| Halberd Corporation | 10.13 Thousand USD | -3970110.246% |
| Enzolytics Inc. | 361.7 Million USD | -11.201% |
| Agentix Corp. | 261.39 Thousand USD | -153776.936% |
| Resverlogix Corp. | 8.11 Million USD | -4856.525% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -21318.941% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 91.145% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -743.197% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -62780.986% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1765502.915% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -4394.525% |
| AVAX Technologies, Inc. | 7.37 Million USD | -5352.263% |
| Zenith Capital Corp. | 7410.00 USD | -5427997.166% |
| Genscript Biotech Corporation | 3.38 Billion USD | 88.122% |
| Ember Therapeutics, Inc. | 184.00 USD | -218598813.043% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -124888.969% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -153793.421% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -43244.71% |
| Kadimastem Ltd | 2.3 Million USD | -17356.946% |
| Helix BioMedix, Inc. | 3.02 Million USD | -13196.217% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -704390.84% |
| LadRx Corporation | 2.3 Million USD | -17328.187% |
| Cell Source, Inc. | 195.17 Thousand USD | -205986.97% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -113645.097% |
| NovAccess Global Inc. | 62.24 Thousand USD | -646060.519% |
| Affymax, Inc. | 7.44 Million USD | -5304.031% |
| Itoco Inc. | 1.4 Million USD | -28628.665% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -420383.603% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -379354.717% |
| Mobile Lads Corp. | 52.00 USD | -773503746.154% |
| CytoDyn Inc. | 11.13 Million USD | -3511.907% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -281229.211% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2249463.758% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -104245.593% |
| SYBLEU INC | 330.46 Thousand USD | -121612.844% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -98141.423% |
| International Stem Cell Corporation | 5.39 Million USD | -7362.375% |
| Bioxytran, Inc. | 137.63 Thousand USD | -292131.796% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2581.153% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -2326.093% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -509041.772% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -46417.023% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -5250.831% |
| Neutra Corp. | 2851.00 USD | -14108002.42% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1141.196% |
| PureTech Health plc | 693.97 Million USD | 42.041% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -4883.491% |
| IXICO plc | 15.84 Million USD | -2438.655% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -4756.581% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -289.282% |
| CSL Limited | 38.02 Billion USD | 98.942% |
| Cellectis S.A. | 333.99 Million USD | -20.428% |